The adjustment in price target by Canaccord Genuity, while maintaining a Buy rating, suggests a positive outlook on Exact Sciences but with a slightly reduced growth expectation. This could lead to a neutral short-term impact on the stock as the market digests the new price target alongside the reaffirmed confidence in the company's prospects.